Skip to main content

Advertisement

SpringerLink
Log in

Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Sarcopenia reportedly predicts poor outcomes in elderly patients with diffuse large B-cell lymphoma (DLBCL). However, because previous studies only involved elderly patients, it is difficult to generalize these results to all patients with DLBCL. We retrospectively analyzed 207 patients with DLBCL who received the R-CHOP or R-THP-COP regimen between June 2004 and May 2014. Sarcopenia was measured by the analysis of CT images at the L3 level before treatment. The surface of muscular tissues was selected according to the CT Hounsfield unit. This value was normalized for stature in order to calculate the L3 skeletal muscle index (L3 SMI, cm2/m2). Median age at diagnosis in the 121 males and 86 females was 67 years (range, 19–86 years). The sex-specific cutoffs for the L3 SMI were determined by receiver operator curve (ROC) analysis. Sarcopenic patients were older than non-sarcopenic patients, with a median age of 70 and 65 years, respectively (p < 0.001). Other International Prognostic Index factors were not significantly different when comparing sarcopenic and non-sarcopenic patients. With a median follow-up of 50.4 months, the 3-year overall survival (OS) was 70 % in the sarcopenic group and 85 % in the non-sarcopenic group (p = 0.0260). In a subgroup analysis by gender, there was a significant difference in the OS when comparing sarcopenic and non-sarcopenic patients in males but not in females (p = 0.0003, p = 0.4440, respectively). Sarcopenia is an independent prognostic factor in male patients with DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon

    Google Scholar 

  2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795

    Article  CAS  PubMed  Google Scholar 

  3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027–5033. doi:10.1200/JCO.2005.09.137

    Article  CAS  PubMed  Google Scholar 

  4. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial G (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391. doi:10.1016/S1470-2045(06)70664-7

    Article  CAS  PubMed  Google Scholar 

  5. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994. doi:10.1056/NEJM199309303291402

    Article  Google Scholar 

  6. Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, Takahashi T, Moriwaki H (2000) Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol 64(4):257–261

    Article  CAS  PubMed  Google Scholar 

  7. Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol 77(3):217–225. doi:10.1111/j.1600-0609.2006.00702.x

    Article  CAS  PubMed  Google Scholar 

  8. Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131(2):73–79. doi:10.1007/s00432-004-0600-9

    Article  CAS  PubMed  Google Scholar 

  9. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13(11):3264–3268. doi:10.1158/1078-0432.CCR-06-3067

    Article  CAS  PubMed  Google Scholar 

  10. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9(7):629–635. doi:10.1016/S1470-2045(08)70153-0

    Article  PubMed  Google Scholar 

  11. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920–2926. doi:10.1158/1078-0432.CCR-08-2242

    Article  CAS  PubMed  Google Scholar 

  12. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15(22):6973–6979. doi:10.1158/1078-0432.CCR-09-1525

    Article  CAS  PubMed  Google Scholar 

  13. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21(8):1594–1598. doi:10.1093/annonc/mdp605

    Article  CAS  PubMed  Google Scholar 

  14. Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, Stamatoullas A, Lepretre S, Tilly H, Jardin F (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55(4):817–823. doi:10.3109/10428194.2013.816421

    Article  CAS  PubMed  Google Scholar 

  15. Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130(2):107–113. doi:10.1007/s00432-003-0508-9

    Article  CAS  PubMed  Google Scholar 

  16. Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Yasuda I, Katsumura N, Takahashi T, Takami T, Moriwaki H (2010) Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol 136(1):65–70. doi:10.1007/s00432-009-0637-x

    Article  CAS  PubMed  Google Scholar 

  17. Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Goto H, Fukuno K, Yamada T, Sawada M, Takahashi T, Takami T, Moriwaki H (2011) Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 52(4):629–634. doi:10.3109/10428194.2011.555024

    Article  CAS  PubMed  Google Scholar 

  18. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31(11):1860–1861

    CAS  PubMed  Google Scholar 

  19. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. doi:10.1182/blood-2006-08-038257

    Article  CAS  PubMed  Google Scholar 

  20. Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22(4):261–268

    Article  CAS  PubMed  Google Scholar 

  21. Takagi T, Oguro M (1987) (2″-R)-4′-o-Tetrahydropyranyladriamycin, a new anthracycline derivative: its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20(2):151–154

    Article  CAS  PubMed  Google Scholar 

  22. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25(3):107–114. doi:10.1002/hon.815

    Article  CAS  PubMed  Google Scholar 

  23. Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68(6):354–361

    Article  CAS  PubMed  Google Scholar 

  24. Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89(9):897–904. doi:10.1007/s00277-010-0956-7

    Article  CAS  PubMed  Google Scholar 

  25. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS (2001) Sarcopenia. J Lab Clin Med 137(4):231–243. doi:10.1067/mlc.2001.113504

    Article  CAS  PubMed  Google Scholar 

  26. Prado CM, Birdsell LA, Baracos VE (2009) The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3(4):269–275. doi:10.1097/SPC.0b013e328331124a

    Article  PubMed  Google Scholar 

  27. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97(6):2333–2338. doi:10.1152/japplphysiol.00744.2004

    Article  PubMed  Google Scholar 

  28. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85(1):115–122

    CAS  PubMed  Google Scholar 

  29. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33(5):997–1006. doi:10.1139/H08-075

    Article  PubMed  Google Scholar 

  30. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577

    CAS  PubMed  Google Scholar 

  31. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. doi:10.1038/bmt.2012.244

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. doi:10.1016/S1470-2045(10)70218-7

    Article  PubMed  Google Scholar 

  33. Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166. doi:10.1016/j.cmet.2012.06.011

    Article  CAS  PubMed  Google Scholar 

  34. Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG, McMillan DC (2012) The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One 7(8):e41883. doi:10.1371/journal.pone.0041883

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Argiles JM, Busquets S, Lopez-Soriano FJ (2005) The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 37(10):2036–2046. doi:10.1016/j.biocel.2005.03.014

    Article  CAS  PubMed  Google Scholar 

  36. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6):448–454. doi:10.1056/NEJM199902113400607

    Article  CAS  PubMed  Google Scholar 

  37. Richards CH, Leitch EF, Horgan PG, Anderson JH, McKee RF, McMillan DC (2010) The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. Br J Cancer 103(9):1356–1361. doi:10.1038/sj.bjc.6605919

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Roxburgh CS, Platt JJ, Leitch EF, Kinsella J, Horgan PG, McMillan DC (2011) Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol 18(4):997–1005. doi:10.1245/s10434-010-1410-8

    Article  CAS  PubMed  Google Scholar 

  39. McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90(2):215–219. doi:10.1002/bjs.4038

    Article  CAS  PubMed  Google Scholar 

  40. Aleman MR, Santolaria F, Batista N, de La Vega M, Gonzalez-Reimers E, Milena A, Llanos M, Gomez-Sirvent JL (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19(1):21–26

    Article  CAS  PubMed  Google Scholar 

  41. Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322. doi:10.1016/j.ccr.2012.02.022

    Article  CAS  PubMed  Google Scholar 

  42. Mamlouk S, Wielockx B (2013) Hypoxia-inducible factors as key regulators of tumor inflammation. Int J Cancer 132(12):2721–2729. doi:10.1002/ijc.27901

    Article  CAS  PubMed  Google Scholar 

  43. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279. doi:10.1146/annurev-med-061509-131248

    Article  CAS  PubMed  Google Scholar 

  44. Riihijarvi S, Taskinen M, Jerkeman M, Leppa S (2011) Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 86(2):124–128. doi:10.1111/j.1600-0609.2010.01541.x

    Article  PubMed  Google Scholar 

  45. Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M (2013) Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study. Leuk Lymphoma 54(1):53–57. doi:10.3109/10428194.2012.691482

    Article  CAS  PubMed  Google Scholar 

  46. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, Zambon P, Gatta G, De Angelis R, Group EW (2009) The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer 45(6):1017–1027. doi:10.1016/j.ejca.2008.11.008

    Article  CAS  PubMed  Google Scholar 

  47. Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119(14):3276–3284. doi:10.1182/blood-2011-09-380949

    Article  PubMed  Google Scholar 

  48. Riggio O, Angeloni S, Ciuffa L, Nicolini G, Attili AF, Albanese C, Merli M (2003) Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. Clin Nutr 22(6):553–559

    Article  CAS  PubMed  Google Scholar 

  49. Peng S, Plank LD, McCall JL, Gillanders LK, McIlroy K, Gane EJ (2007) Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. Am J Clin Nutr 85(5):1257–1266

    CAS  PubMed  Google Scholar 

  50. Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, Boffo G, Caregaro L (2001) Nutrition and survival in patients with liver cirrhosis. Nutrition 17(6):445–450

    Article  CAS  PubMed  Google Scholar 

  51. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R (2002) Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 54(2):131–139

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S (2006) Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 96(5):895–901

    Article  CAS  PubMed  Google Scholar 

  53. Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U (2012) Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 17(6):838–846. doi:10.1634/theoncologist.2011-0417

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Marchesi F, Cenfra N, Altomare L, Dessanti ML, Mecarocci S, Cerchiara E, Rago A, D’Andrea M, Tomarchio V, Olimpieri OM, Tirindelli MC, Mengarelli A, Petti MC, Avvisati G, Cimino G (2013) A retrospective study on 73 elderly patients (>/=75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. J Geriatr Oncol 4(3):242–248. doi:10.1016/j.jgo.2013.04.003

    Article  PubMed  Google Scholar 

  55. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older P (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4):412–423. doi:10.1093/ageing/afq034

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mss. Chiyoko Sano, Hitomi Fujisawa, Shoko Sumi, Eriko Kunishima, and Miho Yagi for their secretarial assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan

    Nobuhiko Nakamura, Takeshi Hara, Yuhei Shibata, Takuro Matsumoto, Hiroshi Nakamura, Soranobu Ninomiya, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Makoto Shiraki, Masahito Shimizu & Hisashi Tsurumi

  2. Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan

    Yusuke Kito & Tamotsu Takeuchi

  3. Pathology Division, Gifu University Hospital, Gifu, Japan

    Tatsuhiko Miyazaki

Authors
  1. Nobuhiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuhei Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuro Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Soranobu Ninomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yusuke Kito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junichi Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nobuhiro Kanemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoe Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Makoto Shiraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tatsuhiko Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tamotsu Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masahito Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hisashi Tsurumi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisashi Tsurumi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, N., Hara, T., Shibata, Y. et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol 94, 2043–2053 (2015). https://doi.org/10.1007/s00277-015-2499-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2499-4

Keywords

Search

Navigation